Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on "Publications" section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE
Vistagen showed early test results for a new anxiety medicine at a medical conference. When a company shares promising research like this, watch to see if larger studies confirm these results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.